Zevra Therapeutics Statistics
Total Valuation
ZVRA has a market cap or net worth of $196.29 million. The enterprise value is $172.31 million.
| Market Cap | 196.29M |
| Enterprise Value | 172.31M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ZVRA has 43.43 million shares outstanding. The number of shares has increased by 2.79% in one year.
| Shares Outstanding | 43.43M |
| Shares Change (YoY) | +2.79% |
| Shares Change (QoQ) | +11.50% |
| Owned by Insiders (%) | 8.08% |
| Owned by Institutions (%) | 29.74% |
| Float | 36.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.15 |
| Forward PS | 6.56 |
| PB Ratio | 3.17 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.18 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29.68 |
Financial Efficiency
Return on equity (ROE) is -68.40% and return on invested capital (ROIC) is -46.96%.
| Return on Equity (ROE) | -68.40% |
| Return on Assets (ROA) | -35.20% |
| Return on Capital (ROIC) | -46.96% |
| Revenue Per Employee | $422,477 |
| Profits Per Employee | -$708,446 |
| Employee Count | 65 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.41% in the last 52 weeks. The beta is 1.84, so ZVRA's price volatility has been higher than the market average.
| Beta (1Y) | 1.84 |
| 52-Week Price Change | -25.41% |
| 50-Day Moving Average | 5.84 |
| 200-Day Moving Average | 5.23 |
| Relative Strength Index (RSI) | 28.94 |
| Average Volume (30 Days) | 250,964 |
Short Selling Information
The latest short interest is 2.25 million, so 5.18% of the outstanding shares have been sold short.
| Short Interest | 2.25M |
| Short Previous Month | 2.13M |
| Short % of Shares Out | 5.18% |
| Short % of Float | 6.24% |
| Short Ratio (days to cover) | 8.63 |
Income Statement
In the last 12 months, ZVRA had revenue of $27.46 million and -$46.05 million in losses. Loss per share was -$1.30.
| Revenue | 27.46M |
| Gross Profit | 24.52M |
| Operating Income | -49.60M |
| Pretax Income | -46.05M |
| Net Income | -46.05M |
| EBITDA | -43.54M |
| EBIT | -44.55M |
| Loss Per Share | -$1.30 |
Balance Sheet
The company has $67.74 million in cash and $43.77 million in debt, giving a net cash position of $23.97 million or $0.55 per share.
| Cash & Cash Equivalents | 67.74M |
| Total Debt | 43.77M |
| Net Cash | 23.97M |
| Net Cash Per Share | $0.55 |
| Equity / Book Value | 61.86M |
| Book Value Per Share | 1.42 |
| Working Capital | 13.22M |
Cash Flow
In the last 12 months, operating cash flow was -$33.54 million and capital expenditures -$296,000, giving a free cash flow of -$33.83 million.
| Operating Cash Flow | -33.54M |
| Capital Expenditures | -296,000 |
| Free Cash Flow | -33.83M |
| FCF Per Share | -$0.95 |
Margins
Gross margin is 89.28%, with operating and profit margins of -180.63% and -167.69%.
| Gross Margin | 89.28% |
| Operating Margin | -180.63% |
| Pretax Margin | -167.69% |
| Profit Margin | -167.69% |
| EBITDA Margin | -158.56% |
| EBIT Margin | -162.22% |
| FCF Margin | -123.20% |
Dividends & Yields
ZVRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.79% |
| Shareholder Yield | -2.79% |
| Earnings Yield | -23.46% |
| FCF Yield | -17.24% |
Analyst Forecast
The average price target for ZVRA is $20.00, which is 342.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 342.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 62.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 28, 2020. It was a reverse split with a ratio of 1:16.
| Last Split Date | Dec 28, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
ZVRA has an Altman Z-Score of -2.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.78 |
| Piotroski F-Score | 3 |